Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Surgery, IJsselland Ziekenhuis, Capelle aan den IJssel, The Netherlands.
Ann Surg. 2022 Jul 1;276(1):55-65. doi: 10.1097/SLA.0000000000005422. Epub 2022 Feb 18.
To assess prevalence of hernia recurrence, surgical site infection (SSI), seroma, serious complications, and mortality after retro-rectus repair.
Ventral abdominal wall hernia is a common problem, tied to increasing frailty and obesity of patients undergoing surgery. For noncomplex ventral hernia, retro-rectus (Rives-Stoppa) repair is considered the gold standard treatment. Level-1 evidence confirming this presumed superiority is lacking.
Five databases were searched for studies reporting on retro-rectus repair. Single-armed and comparative randomized and non-randomized studies were included. Outcomes were pooled with mixed-effects, inverse variance or random-effects models.
Ninety-three studies representing 12,440 patients undergoing retro-rectus repair were included. Pooled hernia recurrence was estimated at 3.2% [95% confidence interval (CI): 2.2%-4.2%, n = 11,049] after minimally 12months and 4.1%, (95%CI: 2.9%-5.5%, n = 3830) after minimally 24 months. Incidences of SSI and seroma were estimated at respectively 5.2% (95%CI: 4.2%-6.4%, n = 4891) and 5.5% (95%CI: 4.4%-6.8%, n = 3650). Retro-rectus repair was associated with lower recurrence rates compared to onlay repair [odds ratios (OR): 0.27, 95%CI: 0.15-0.51, P < 0.001] and equal recurrence rates compared to intraperitoneal onlay mesh (IPOM) repair (OR: 0.92, 95%CI: 0.75-1.12, P = 0.400). Retro-rectus repair was associated with more SSI than IPOM repair (OR: 1.8, 95%CI: 1.03 -3.14, P = 0.038). Minimally invasive retro-rectus repair displayed low rates of recurrence (1.3%, 95%CI: 0.7%-2.3%, n = 849) and SSI (1.5%, 95%CI: 0.8%-2.8%, n = 982), albeit based on non-randomized studies.
Retro-rectus (Rives-Stoppa) repair results in excellent outcomes, superior or similar to other techniques for all outcomes except SSI. The latter rarely occurred, yet less frequently after IPOM repair, which is usually performed by laparoscopy.
评估后入路修复后疝复发、手术部位感染(SSI)、血清肿、严重并发症和死亡率的发生率。
腹壁疝是一种常见的问题,与接受手术的患者日益虚弱和肥胖有关。对于非复杂的腹壁疝,后入路(Rives-Stoppa)修复被认为是金标准治疗。缺乏证实这种假定优势的 1 级证据。
检索了 5 个数据库,以寻找报告后入路修复的研究。包括单臂和比较随机和非随机研究。使用混合效应、逆方差或随机效应模型对结果进行汇总。
93 项研究共纳入 12440 例接受后入路修复的患者。12 个月后,最小随访时间为 12 个月时,疝复发率估计为 3.2%[95%置信区间(CI):2.2%-4.2%,n=11049],24 个月后,最小随访时间为 24 个月时,复发率估计为 4.1%[95%CI:2.9%-5.5%,n=3830]。SSI 和血清肿的发生率分别估计为 5.2%[95%CI:4.2%-6.4%,n=4891]和 5.5%[95%CI:4.4%-6.8%,n=3650]。与外侧修补术相比,后入路修复与较低的复发率相关[比值比(OR):0.27,95%CI:0.15-0.51,P<0.001],与腹腔内外侧网片修补术(IPOM)修复的复发率相当(OR:0.92,95%CI:0.75-1.12,P=0.400)。与 IPOM 修复相比,后入路修复与更多的 SSI 相关(OR:1.8,95%CI:1.03-3.14,P=0.038)。微创后入路修复的复发率(1.3%,95%CI:0.7%-2.3%,n=849)和 SSI(1.5%,95%CI:0.8%-2.8%,n=982)较低,尽管基于非随机研究。
后入路(Rives-Stoppa)修复的结果非常好,除了 SSI 之外,在所有结果上均优于或等同于其他技术。后者很少发生,但在 IPOM 修复后发生率较低,IPOM 修复通常通过腹腔镜进行。